News
Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™
08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently...
read more 
Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
28-04-2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants.
ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data...
read more
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium
- Kiadis Pharma presents at the EBMT in Göteborg
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting
Kiadis Pharma
Entrada 231-234
1096 EG Amsterdam
The Netherlands
T +31 (0)20 314 02 50
F +31 (0)20 314 02 51
